SNDX vs UNH

Syndax shows strong commercial momentum with Revuforj and Niktimvo sales annualizing near $200 million each, validating its market opportunity in oncology with 224% YoY revenue growth. The significant narrowing of net loss in Q1 2026, beating EPS estimates, addresses prior profitability concerns and indicates a better path towards sustainable operations, despite a minor revenue miss. The company m...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...